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Abstract
RP is an exaggerated vasospastic response to cold or emotion. Randomized, double-blind, placebo-
controlled trials with either parallel group or cross-over trials should be mainly considered. Cross-over
design, which is good for early phase trials of immediate or very short-term outcomes, is important in a
condition as heterogeneous as RP: a wash-out period between treatment arms should always be included
to minimize the possibility of a period (carry-over) effect. Duration of RP trials is usually constrained by the
need to complete these over a single season, usually winter when the weather is colder. For cross-over
trials, each treatment arm tends to be 4 weeks or less. Frequency and duration of attacks, and the
Raynaud’s Condition Score are widely used outcome measures. There is increasing interest in physio-
logical laboratory endpoints, for example laser Doppler imaging at least for early phase trials.
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Rheumatology key messages
. The majority of patients with SSc-related RP should be offered treatment.
. Randomized, double-blind, controlled trials to test new RP therapies remain the standard.
. Most definitive trials of RP will need to be multicentre to achieve adequate power.
Introduction
RP is essentially an exaggerated vasospastic response to
cold or emotion (stress) [1, 2]. In the classic triphasic
response, the digits turn white (ischaemia), then blue (hyp-
oxia) and then red (reperfusion). When mild, RP is uncom-
fortable but has minimal impact on quality of life [3]; this is
the situation for many patients with primary (idiopathic) RP.
At the other extreme, RP, when associated with CTDs
such as SSc (secondary RP), can progress to irreversible
tissue injury with skin ulceration and sometimes gangrene;
digital skin ulceration occurs in the order of 50% of pa-
tients (probably more) at some point in their disease
course [46]. Gangrene may also occur in patients with
underlying CTD, particularly SSc, although much less fre-
quently than digital ulceration [7].
These points to consider for a clinical trial in SSc derive
from general experience, literature when available and
consensus among experts. Thus while the evidence may
be Class A through D, the Recommendations are often
Class C, except where noted.
Objective
To suggest points to consider in conducting clinical trials
in SSc-associated RP. Clinical trials specifically targeting
digital ulceration (an end point of severe digital ischaemia)
are considered elsewhere.
Trial design
We recommend that strong consideration be given to
designing randomized, double-blind, placebo-controlled
1Research Laboratories and Division of Clinical Rheumatology,
Department of Internal Medicine, IRCCS, University of Genova,
Genova, Italy, 2Department of Rheumatology, Ghent University
Hospital, 3Faculty of Internal Medicine, Ghent University, Ghent,
Belgium, 4Department of Rheumatology, Department of Medicine,
David Geffen School of Medicine at UCLA, Los Angeles, CA,
5Department of Medicine University of Michigan, University of
Michigan Scleroderma Program, Ann Arbor, MI and 6The University of
Manchester, Salford Royal NHS Foundation Trust, Manchester and
NIHR Manchester Musculoskeletal Biomedical Research Unit, Central
Manchester NHS Foundation Trust, Manchester Academic Health
Science Centre, UK
Correspondence to: Maurizio Cutolo, Research Laboratories and
Division of Clinical Rheumatology, Department of Internal Medicine,
IRCCS, University of Genova, Viale Benedetto XV, 6 16132 Genova,
Italy.
E-mail: mcutolo@unige.it
Submitted 1 July 2015; revised version accepted 12 April 2017









trials, although sometimes a comparator drug (e.g. a cal-
cium channel blocker [8]) is included rather than placebo.
Trials may be either parallel group [912] or cross-over
trials [13]. A cross-over design, which is good for early
phase trials of immediate or very short-term outcomes,
has the advantage of allowing each patient to act as his/
her own control, and this is important in a condition as
heterogeneous as RP. A disadvantage of the cross-over
trial is that there may be a period effect, although a wash-
out period between treatments [13] can minimize this.
Single-dose studies, examining acute effects of vaso-
dilators, can be considered at an early stage of drug de-
velopment [14] and are usually of cross-over design.
Duration of RP trials is usually constrained by the need
to complete these over a single season, usually winter
when the weather is colder in the latitudes where there
are large temperature differences. For this reason trial dur-
ation is usually short. For parallel group trials, duration has
usually been 46 weeks [9, 11, 15] but may be up to
4 months [16].
For cross-over trials, each treatment arm tends to be
4 weeks or less [13]. If the study question is more broad
ranging than short-term safety and efficacy in RP, for ex-
ample, if effects on peripheral vascular structure and/or
vascular remodeling are being examined (even if indir-
ectly), then a longer duration may be appropriate [10].
Because SSc-related RP is a long-term condition, there
is a good rationale for long term trials (i.e. 23 years) [10].
Methods
Inclusion criteria
In addition to having SSc and RP, a patient must have
sufficiently frequent attacks to allow a realistic measure-
ment of improvement. Therefore, studies usually specify
for inclusion a minimum number of attacks per week
[9, 11, 15].
Inclusion criteria usually include the ACR/EULAR 2013
criteria [17, 18] but may also allow recruitment of patients
who fulfil any validated criteria for SSc. The LeRoy and
Medsger criteria include either an SSc-specific autoanti-
body and/or abnormal nailfold capillaroscopy [19, 20] and
so allow inclusion of patients likely to have SSc (and who
often have severe RP) but who do not (at least as yet) fulfil
the 2013 criteria. Other options such as stratification by
RP type will allow for balance between the treatment
groups.
Confounding variables
Because most drugs examined in clinical trials of RP have
vasoactive effects, patients who have any underlying dis-
ease that might jeopardize assessment of vasodilation, or
in whom special caution is required, are generally
excluded, for example, patients with ischaemic heart dis-
ease or cerebrovascular disease.
In phase 3 trials inclusion criteria should be as broad as
possible, so if potential confounding medications are to
be allowed, then washout, stratification, stability on the
medications with continued frequency of RP and
accounting of potential confounding medications will be
important.
Smoking has effects on the vasculature. Although it
could be strongly argued that smokers should be
excluded from clinical trials of RP, this may make results
of the study less generalizable. If smokers are to be
allowed, the duration and intensity of smoking should be
recorded and accounted in the analysis. Therefore data
on smoking should be collected at the baseline visit.
As for concomitant and confounding medications, con-
founding illnesses need to be considered and accounted.
They can be excluded, although this may hinder recruit-
ment. Recording the concomitant illnesses and including
them in the analysis and/or allowing a limited number of
concomitant illnesses that are stable are other alternatives.
Outcome variables
Frequency of Raynaud’s attacks, duration of Raynaud’s
attacks and the Raynaud’s Condition Score are outcome
measures [21] that are sensitive to change and that are
widely used in clinical trials. The only fully validated
Raynaud’s phenomenon measure is the Raynaud’s
Condition Score [20]. It is a daily self-assessment incor-
porating frequency, duration, severity and impact of RP
attacks on a 010 ordinal scale [21].
Other measures that can be used are patient’s and
physician’s assessment of RP activity on a visual ana-
logue scale measures of disability (e.g. the HAQ
Disability Index) and of psychological impact [21].
If these measures, which are not validated in SSc, are to
be used as primary measures, it is advisable to do a small
study to validate them before using them as a primary
measure in a phase 3 trial. If it is chosen to use one of
the unvalidated measures without prior validation, it might
be advisable to use it/them as a secondary or exploratory
measure or use it/them in phase 2 trials [11].
A recent large study showed that a combination test
improved test characteristics compared with individual
measures. This should be considered during trial design
[22]. There is increasing interest in physiological labora-
tory endpoints, for example, thermography, laser Doppler
imaging [23] and finger systolic pressure measurements
[24]. Although most require further evaluation, these are
possible endpoints for early phase trials, although not
feasible for phase 3 multicentre clinical trials.
Exploratory endpoints may be appropriately investi-
gated in small open-label [25] or single dose studies
[26]. Microvascular structural abnormalities, as assessed
by nailfold capillaroscopy [27], may be an end point in
clinical trials of vascular remodelling agents in patients
with SSc-related RP, as recently shown [2830]. Other
end-points may be appropriate depending on the mech-
anism of action of the drug being evaluated [31, 32].
Digital ulceration is often included as an end point in clin-
ical trials of RP but is discussed elsewhere.
Analysis
A full analytic plan is required before starting a clinical trial.
At a minimum, analyses should include patient disposition
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(as a table or figure) and another table describing patient
groups at enrolment including demographics, ancillary
disease characteristics and baseline values for outcome
measurements. Comparisons among the groups to estab-
lish baseline uniformity are strongly recommended.
Most definitive trials of Raynaud’s phenomenon will
need to be multicentre to achieve adequate power and
power analysis prior to starting a trial should be strongly
considered, especially for phases 2 and 3 trials. Phase 1
trials may not require power analysis. A predefined ana-
lysis plan that includes an algorithm to deal with missing
data and drop-outs (and the reasons for dropping out)
should also be strongly considered.
Safety and publication
Finally, safety issues must be carefully evaluated in de-
signing new trials [33]. Results should be presented wher-
ever possible according to the CONSORT guidelines [34].
Conclusion
The majority of patients with SSc-related RP should be
offered treatment. Randomized, double-blind, controlled
trials to test new RP therapies remain the standard. Most
trials of RP will need to be multicentre to achieve ad-
equate power.
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